Performance of the Abbott RealTime HIV-1 Viral Load Assay Is Not Impacted by Integrase Inhibitor Resistance-Associated Mutations | Zendy

Thomas P. Young | Zendy; Gavin Cloherty | Zendy; Signe Fransen | Zendy; Laura A. Napolitano | Zendy; Priscilla Swanson | Zendy; Christine Herman | Zendy; Neil Parkin | Zendy; John Hackett | Zendy

Open Access

Performance of the Abbott RealTime HIV-1 Viral Load Assay Is Not Impacted by Integrase Inhibitor Resistance-Associated Mutations

Author(s) -

Thomas P. Young,

Gavin Cloherty,

Signe Fransen,

Laura A. Napolitano,

Priscilla Swanson,

Christine Herman,

Neil Parkin,

John Hackett

Publication year - 2011

Publication title -

journal of clinical microbiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.349

H-Index - 255

eISSN - 1070-633X

pISSN - 0095-1137

DOI - 10.1128/jcm.02253-10

Subject(s) - raltegravir , integrase , integrase inhibitor , viral load , virology , human immunodeficiency virus (hiv) , biology , lentivirus , microbiology and biotechnology , viral disease , antiretroviral therapy

The Abbott RealTime HIV-1 viral load assay uses primers and probes targeted to integrase, which is also the target of integrase inhibitors such as raltegravir. Viral loads of 42 raltegravir-susceptible and 40 raltegravir-resistant specimens were determined using RealTime HIV-1 and Roche Monitor (v1.5). The differences in viral load measurements between assays were comparable in the two groups, demonstrating that the RealTime HIV-1 assay can tolerate raltegravir-selected mutations.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research